Context Therapeutics Reports 29% Response Rate for CTIM-76 in Platinum-Resistant Ovarian Cancer Phase 1 Trial

BioPharm International·Jun 16

This story is reported by BioPharm International. Read what other outlets are saying below, then open the original report for full details.